Jayashree Kalpathy-Cramer
Concepts (402)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 35 | 2026 | 161 | 6.390 |
Why?
| | Artificial Intelligence | 38 | 2025 | 334 | 5.430 |
Why?
| | Image Processing, Computer-Assisted | 24 | 2026 | 772 | 4.540 |
Why?
| | Glioblastoma | 15 | 2024 | 347 | 3.090 |
Why?
| | Brain Neoplasms | 23 | 2024 | 1304 | 3.050 |
Why?
| | Machine Learning | 23 | 2026 | 553 | 2.920 |
Why?
| | Algorithms | 38 | 2024 | 1763 | 2.430 |
Why?
| | Uterine Cervical Neoplasms | 8 | 2025 | 287 | 2.380 |
Why?
| | Diagnostic Imaging | 19 | 2024 | 326 | 2.200 |
Why?
| | Radiology | 10 | 2024 | 170 | 1.930 |
Why?
| | Natural Language Processing | 7 | 2023 | 99 | 1.870 |
Why?
| | Magnetic Resonance Imaging | 41 | 2024 | 3709 | 1.840 |
Why?
| | Information Storage and Retrieval | 8 | 2015 | 120 | 1.720 |
Why?
| | Retina | 7 | 2026 | 314 | 1.570 |
Why?
| | Neuroimaging | 7 | 2022 | 272 | 1.530 |
Why?
| | Glioma | 8 | 2022 | 427 | 1.420 |
Why?
| | Cervix Uteri | 3 | 2025 | 53 | 1.370 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 5 | 2016 | 142 | 1.280 |
Why?
| | Image Interpretation, Computer-Assisted | 13 | 2025 | 278 | 1.210 |
Why?
| | ROC Curve | 16 | 2026 | 586 | 1.070 |
Why?
| | Software | 10 | 2024 | 676 | 1.070 |
Why?
| | Papillomavirus Infections | 5 | 2025 | 380 | 1.070 |
Why?
| | Humans | 162 | 2026 | 141187 | 1.040 |
Why?
| | Colposcopy | 2 | 2025 | 22 | 1.010 |
Why?
| | Optic Disk | 2 | 2025 | 52 | 0.980 |
Why?
| | Optical Imaging | 1 | 2026 | 66 | 0.920 |
Why?
| | Glaucoma | 2 | 2025 | 241 | 0.900 |
Why?
| | Tomography, X-Ray Computed | 15 | 2023 | 2746 | 0.880 |
Why?
| | Fundus Oculi | 6 | 2026 | 86 | 0.880 |
Why?
| | Geographic Atrophy | 1 | 2026 | 91 | 0.880 |
Why?
| | Severity of Illness Index | 9 | 2024 | 2892 | 0.870 |
Why?
| | Telemedicine | 7 | 2023 | 891 | 0.860 |
Why?
| | Gestational Age | 18 | 2026 | 957 | 0.850 |
Why?
| | Tomography, Optical Coherence | 2 | 2025 | 257 | 0.840 |
Why?
| | Reproducibility of Results | 28 | 2025 | 3348 | 0.830 |
Why?
| | Infant, Newborn | 35 | 2026 | 6275 | 0.820 |
Why?
| | Radiology Information Systems | 4 | 2022 | 31 | 0.790 |
Why?
| | Solitary Pulmonary Nodule | 3 | 2021 | 21 | 0.790 |
Why?
| | Privacy | 1 | 2023 | 42 | 0.780 |
Why?
| | Ophthalmology | 5 | 2023 | 105 | 0.780 |
Why?
| | Breast Neoplasms | 7 | 2024 | 2250 | 0.770 |
Why?
| | Diagnostic Techniques, Ophthalmological | 3 | 2018 | 50 | 0.760 |
Why?
| | Ophthalmoscopy | 8 | 2024 | 38 | 0.710 |
Why?
| | Radiologists | 4 | 2024 | 52 | 0.710 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2026 | 395 | 0.670 |
Why?
| | Sensitivity and Specificity | 14 | 2024 | 1973 | 0.660 |
Why?
| | Crowdsourcing | 1 | 2020 | 18 | 0.660 |
Why?
| | Medicine | 1 | 2021 | 125 | 0.630 |
Why?
| | Retinal Vessels | 6 | 2024 | 75 | 0.620 |
Why?
| | Retrospective Studies | 27 | 2026 | 16273 | 0.610 |
Why?
| | Breast Density | 3 | 2024 | 7 | 0.610 |
Why?
| | Mammography | 4 | 2024 | 159 | 0.590 |
Why?
| | Stroke | 3 | 2023 | 1154 | 0.580 |
Why?
| | Retinal Vein | 4 | 2021 | 13 | 0.550 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2017 | 72 | 0.530 |
Why?
| | Female | 58 | 2026 | 75515 | 0.520 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 109 | 0.500 |
Why?
| | Lung Neoplasms | 5 | 2021 | 2560 | 0.490 |
Why?
| | Tumor Burden | 4 | 2023 | 312 | 0.490 |
Why?
| | Phenylurea Compounds | 1 | 2016 | 95 | 0.490 |
Why?
| | Databases, Factual | 8 | 2021 | 1444 | 0.470 |
Why?
| | Quinolines | 1 | 2016 | 160 | 0.470 |
Why?
| | Gallbladder Neoplasms | 3 | 2011 | 19 | 0.470 |
Why?
| | Peripheral Arterial Disease | 4 | 2023 | 490 | 0.460 |
Why?
| | Radiography, Thoracic | 5 | 2022 | 178 | 0.450 |
Why?
| | Prostatic Neoplasms | 5 | 2024 | 1048 | 0.450 |
Why?
| | Pattern Recognition, Automated | 5 | 2023 | 74 | 0.450 |
Why?
| | Neonatal Screening | 5 | 2026 | 172 | 0.450 |
Why?
| | Benchmarking | 6 | 2024 | 188 | 0.440 |
Why?
| | Infant, Premature | 10 | 2026 | 597 | 0.440 |
Why?
| | Hypertension, Pulmonary | 1 | 2026 | 1936 | 0.430 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2025 | 45 | 0.430 |
Why?
| | Delivery of Health Care | 1 | 2021 | 961 | 0.430 |
Why?
| | Subtraction Technique | 1 | 2014 | 25 | 0.430 |
Why?
| | Early Detection of Cancer | 5 | 2025 | 441 | 0.420 |
Why?
| | Radiation Oncology | 2 | 2014 | 86 | 0.420 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 1073 | 0.420 |
Why?
| | Retinal Artery | 3 | 2021 | 17 | 0.420 |
Why?
| | Chemoradiotherapy | 6 | 2018 | 232 | 0.420 |
Why?
| | Male | 52 | 2026 | 69783 | 0.420 |
Why?
| | Photography | 6 | 2021 | 115 | 0.420 |
Why?
| | Vocabulary, Controlled | 1 | 2014 | 47 | 0.420 |
Why?
| | White Matter | 3 | 2023 | 147 | 0.410 |
Why?
| | Phantoms, Imaging | 7 | 2023 | 150 | 0.400 |
Why?
| | Multimodal Imaging | 1 | 2014 | 120 | 0.400 |
Why?
| | Datasets as Topic | 5 | 2021 | 125 | 0.380 |
Why?
| | Survival Analysis | 4 | 2016 | 1319 | 0.370 |
Why?
| | Middle Aged | 31 | 2025 | 34434 | 0.360 |
Why?
| | Aged | 29 | 2025 | 24574 | 0.360 |
Why?
| | Cerebral Blood Volume | 3 | 2020 | 5 | 0.360 |
Why?
| | Contrast Media | 9 | 2020 | 470 | 0.350 |
Why?
| | Radiotherapy, Conformal | 1 | 2011 | 73 | 0.350 |
Why?
| | Internet | 2 | 2014 | 690 | 0.350 |
Why?
| | Mass Screening | 4 | 2025 | 1310 | 0.350 |
Why?
| | Adrenoleukodystrophy | 2 | 2023 | 9 | 0.340 |
Why?
| | Clinical Competence | 2 | 2016 | 1202 | 0.340 |
Why?
| | Proportional Hazards Models | 4 | 2011 | 1261 | 0.330 |
Why?
| | Brain | 8 | 2021 | 2858 | 0.330 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 2 | 2023 | 118 | 0.320 |
Why?
| | Precision Medicine | 3 | 2024 | 434 | 0.320 |
Why?
| | Medical Informatics | 4 | 2020 | 101 | 0.310 |
Why?
| | Head and Neck Neoplasms | 5 | 2020 | 553 | 0.310 |
Why?
| | Neoplasms | 7 | 2024 | 2741 | 0.300 |
Why?
| | Database Management Systems | 1 | 2008 | 51 | 0.290 |
Why?
| | User-Computer Interface | 4 | 2015 | 164 | 0.280 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2008 | 219 | 0.280 |
Why?
| | Endovascular Procedures | 2 | 2023 | 355 | 0.280 |
Why?
| | Automation | 5 | 2020 | 100 | 0.270 |
Why?
| | Observer Variation | 4 | 2024 | 355 | 0.270 |
Why?
| | Infant | 12 | 2026 | 9818 | 0.260 |
Why?
| | Lung | 6 | 2022 | 4134 | 0.260 |
Why?
| | Prognosis | 9 | 2024 | 4073 | 0.260 |
Why?
| | Adult | 26 | 2025 | 39177 | 0.250 |
Why?
| | Radiography | 5 | 2022 | 844 | 0.240 |
Why?
| | Risk Factors | 9 | 2026 | 10438 | 0.230 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2018 | 155 | 0.230 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2007 | 232 | 0.230 |
Why?
| | Predictive Value of Tests | 5 | 2025 | 2070 | 0.230 |
Why?
| | Uncertainty | 1 | 2026 | 138 | 0.230 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 2166 | 0.230 |
Why?
| | Rectal Neoplasms | 2 | 2021 | 152 | 0.230 |
Why?
| | Oropharyngeal Neoplasms | 2 | 2015 | 54 | 0.230 |
Why?
| | Reference Standards | 7 | 2021 | 186 | 0.220 |
Why?
| | Neoplasm Grading | 3 | 2024 | 316 | 0.210 |
Why?
| | Adenocarcinoma in Situ | 1 | 2023 | 1 | 0.210 |
Why?
| | Forecasting | 3 | 2019 | 384 | 0.210 |
Why?
| | Statistics as Topic | 2 | 2014 | 302 | 0.200 |
Why?
| | Postoperative Care | 2 | 2019 | 279 | 0.200 |
Why?
| | Ranibizumab | 1 | 2023 | 21 | 0.200 |
Why?
| | Imaging, Three-Dimensional | 4 | 2023 | 567 | 0.200 |
Why?
| | Radiotherapy, Intensity-Modulated | 4 | 2016 | 137 | 0.190 |
Why?
| | Neovascularization, Pathologic | 3 | 2024 | 296 | 0.190 |
Why?
| | Diagnosis, Computer-Assisted | 2 | 2021 | 90 | 0.190 |
Why?
| | Biomedical Research | 3 | 2024 | 703 | 0.190 |
Why?
| | Long QT Syndrome | 1 | 2023 | 70 | 0.190 |
Why?
| | Documentation | 2 | 2015 | 199 | 0.190 |
Why?
| | Macular Degeneration | 1 | 2024 | 186 | 0.190 |
Why?
| | Oxygen | 2 | 2021 | 993 | 0.190 |
Why?
| | Computer Communication Networks | 2 | 2020 | 33 | 0.180 |
Why?
| | Quality Assurance, Health Care | 2 | 2014 | 331 | 0.180 |
Why?
| | Rheumatic Diseases | 1 | 2022 | 92 | 0.180 |
Why?
| | Diverticulitis | 1 | 2021 | 8 | 0.180 |
Why?
| | Patient-Specific Modeling | 2 | 2024 | 42 | 0.180 |
Why?
| | Biomarkers | 4 | 2018 | 4174 | 0.170 |
Why?
| | Cohort Studies | 6 | 2022 | 5799 | 0.170 |
Why?
| | Hospital Units | 1 | 2021 | 32 | 0.170 |
Why?
| | Racism | 1 | 2023 | 139 | 0.170 |
Why?
| | Musculoskeletal System | 1 | 2021 | 49 | 0.170 |
Why?
| | Intestinal Obstruction | 1 | 2021 | 52 | 0.170 |
Why?
| | India | 1 | 2021 | 208 | 0.170 |
Why?
| | Dacarbazine | 3 | 2015 | 98 | 0.170 |
Why?
| | Tibial Meniscus Injuries | 1 | 2021 | 49 | 0.170 |
Why?
| | Perfusion Imaging | 1 | 2020 | 62 | 0.160 |
Why?
| | Microcirculation | 2 | 2017 | 150 | 0.160 |
Why?
| | Radiometry | 1 | 2020 | 54 | 0.160 |
Why?
| | Hyperemia | 1 | 2020 | 49 | 0.160 |
Why?
| | Biomarkers, Tumor | 3 | 2016 | 1251 | 0.160 |
Why?
| | Health Information Exchange | 1 | 2020 | 24 | 0.160 |
Why?
| | Medical Records Systems, Computerized | 2 | 2013 | 96 | 0.160 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2015 | 642 | 0.160 |
Why?
| | Brain Ischemia | 1 | 2023 | 349 | 0.160 |
Why?
| | Signal Processing, Computer-Assisted | 2 | 2017 | 151 | 0.160 |
Why?
| | Brain Diseases | 1 | 2021 | 149 | 0.160 |
Why?
| | Area Under Curve | 4 | 2021 | 324 | 0.160 |
Why?
| | Cerebellar Neoplasms | 1 | 2022 | 179 | 0.160 |
Why?
| | Lung Injury | 1 | 2022 | 227 | 0.160 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2020 | 109 | 0.150 |
Why?
| | Low Back Pain | 1 | 2021 | 108 | 0.150 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2023 | 550 | 0.150 |
Why?
| | Appendicitis | 1 | 2021 | 139 | 0.150 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2023 | 668 | 0.150 |
Why?
| | Medulloblastoma | 1 | 2022 | 218 | 0.150 |
Why?
| | Antineoplastic Agents, Alkylating | 2 | 2018 | 71 | 0.150 |
Why?
| | Aneurysm, Ruptured | 1 | 2019 | 35 | 0.150 |
Why?
| | Capillary Permeability | 1 | 2019 | 149 | 0.150 |
Why?
| | Age Determination by Skeleton | 1 | 2018 | 15 | 0.150 |
Why?
| | Blood-Brain Barrier | 2 | 2017 | 144 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 830 | 0.150 |
Why?
| | Models, Biological | 4 | 2024 | 1828 | 0.150 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2018 | 31 | 0.140 |
Why?
| | Colonic Neoplasms | 1 | 2021 | 246 | 0.140 |
Why?
| | Linear Models | 1 | 2021 | 857 | 0.140 |
Why?
| | Intracranial Aneurysm | 1 | 2019 | 98 | 0.140 |
Why?
| | Arteries | 2 | 2019 | 263 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 852 | 0.140 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2021 | 243 | 0.140 |
Why?
| | Medical Record Linkage | 1 | 2018 | 68 | 0.140 |
Why?
| | Global Health | 1 | 2021 | 386 | 0.140 |
Why?
| | Prospective Studies | 7 | 2023 | 7739 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1787 | 0.130 |
Why?
| | Gadolinium | 1 | 2017 | 81 | 0.130 |
Why?
| | Polysaccharides, Bacterial | 1 | 2017 | 70 | 0.130 |
Why?
| | Bayes Theorem | 2 | 2016 | 417 | 0.130 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1498 | 0.130 |
Why?
| | Preoperative Period | 1 | 2017 | 142 | 0.130 |
Why?
| | Treatment Outcome | 7 | 2023 | 11120 | 0.130 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 326 | 0.130 |
Why?
| | Gray Matter | 1 | 2018 | 85 | 0.130 |
Why?
| | Patient Readmission | 1 | 2022 | 706 | 0.130 |
Why?
| | North America | 3 | 2024 | 306 | 0.130 |
Why?
| | Skin Diseases, Genetic | 1 | 2016 | 13 | 0.130 |
Why?
| | Computer Simulation | 5 | 2024 | 1015 | 0.130 |
Why?
| | Chronic Pain | 1 | 2021 | 280 | 0.120 |
Why?
| | Pharyngeal Muscles | 1 | 2016 | 5 | 0.120 |
Why?
| | Blood Vessels | 1 | 2017 | 180 | 0.120 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2016 | 20 | 0.120 |
Why?
| | SEER Program | 3 | 2011 | 220 | 0.120 |
Why?
| | Angiogenesis Inhibitors | 2 | 2016 | 230 | 0.120 |
Why?
| | National Cancer Institute (U.S.) | 3 | 2020 | 48 | 0.120 |
Why?
| | Blood Volume Determination | 1 | 2015 | 5 | 0.120 |
Why?
| | Risk Assessment | 4 | 2025 | 3490 | 0.120 |
Why?
| | Vascular Malformations | 1 | 2016 | 51 | 0.120 |
Why?
| | Liver Cirrhosis | 1 | 2017 | 282 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 819 | 0.120 |
Why?
| | Positron-Emission Tomography | 4 | 2021 | 310 | 0.110 |
Why?
| | Fibrosis | 1 | 2017 | 541 | 0.110 |
Why?
| | Cranial Irradiation | 1 | 2015 | 85 | 0.110 |
Why?
| | Physical Phenomena | 1 | 2014 | 13 | 0.110 |
Why?
| | Organs at Risk | 1 | 2014 | 35 | 0.110 |
Why?
| | Societies, Medical | 3 | 2024 | 855 | 0.110 |
Why?
| | Radiation Injuries | 1 | 2016 | 149 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2018 | 7856 | 0.110 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2902 | 0.110 |
Why?
| | Birth Weight | 3 | 2023 | 515 | 0.110 |
Why?
| | Brachial Plexus | 1 | 2014 | 33 | 0.110 |
Why?
| | Tumor Microenvironment | 1 | 2018 | 692 | 0.110 |
Why?
| | Administration, Oral | 1 | 2016 | 803 | 0.110 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2011 | 44 | 0.110 |
Why?
| | Deglutition Disorders | 1 | 2016 | 148 | 0.110 |
Why?
| | Joint Instability | 1 | 2016 | 168 | 0.110 |
Why?
| | Mutation | 3 | 2024 | 4013 | 0.100 |
Why?
| | Computer-Assisted Instruction | 1 | 2014 | 68 | 0.100 |
Why?
| | Arteriovenous Malformations | 1 | 2013 | 29 | 0.100 |
Why?
| | Computer Literacy | 1 | 2013 | 5 | 0.100 |
Why?
| | Bias | 3 | 2024 | 229 | 0.100 |
Why?
| | Health Information Systems | 1 | 2013 | 17 | 0.100 |
Why?
| | Young Adult | 7 | 2018 | 13673 | 0.100 |
Why?
| | Survival Rate | 3 | 2018 | 1970 | 0.090 |
Why?
| | Terminology as Topic | 1 | 2014 | 244 | 0.090 |
Why?
| | Otorhinolaryngologic Neoplasms | 1 | 2011 | 2 | 0.090 |
Why?
| | Nomograms | 1 | 2011 | 58 | 0.090 |
Why?
| | Feasibility Studies | 2 | 2014 | 1018 | 0.090 |
Why?
| | Workload | 1 | 2013 | 166 | 0.090 |
Why?
| | Research Design | 2 | 2014 | 1143 | 0.080 |
Why?
| | Child | 8 | 2024 | 22308 | 0.080 |
Why?
| | Support Vector Machine | 2 | 2021 | 38 | 0.080 |
Why?
| | Muscle, Skeletal | 1 | 2020 | 1752 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 2172 | 0.080 |
Why?
| | Liver | 1 | 2017 | 1819 | 0.080 |
Why?
| | Periodicals as Topic | 1 | 2012 | 217 | 0.080 |
Why?
| | Papillomaviridae | 2 | 2023 | 133 | 0.070 |
Why?
| | Oregon | 1 | 2008 | 78 | 0.070 |
Why?
| | Exercise | 1 | 2020 | 2103 | 0.070 |
Why?
| | United States | 5 | 2024 | 15220 | 0.070 |
Why?
| | Total Quality Management | 1 | 2008 | 61 | 0.070 |
Why?
| | Lower Extremity | 2 | 2023 | 439 | 0.070 |
Why?
| | MEDLINE | 1 | 2008 | 23 | 0.070 |
Why?
| | Dilatation, Pathologic | 2 | 2018 | 60 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2024 | 5200 | 0.070 |
Why?
| | Breast | 2 | 2019 | 158 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 914 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2015 | 1122 | 0.060 |
Why?
| | Monte Carlo Method | 2 | 2017 | 150 | 0.060 |
Why?
| | Cluster Analysis | 1 | 2007 | 521 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2019 | 273 | 0.060 |
Why?
| | Tanzania | 1 | 2025 | 59 | 0.060 |
Why?
| | Vaginal Smears | 1 | 2025 | 61 | 0.060 |
Why?
| | Proof of Concept Study | 1 | 2024 | 85 | 0.050 |
Why?
| | Critical Illness | 2 | 2021 | 837 | 0.050 |
Why?
| | Netherlands | 1 | 2024 | 87 | 0.050 |
Why?
| | Intensive Care Units, Neonatal | 2 | 2018 | 268 | 0.050 |
Why?
| | Kinetics | 2 | 2019 | 1652 | 0.050 |
Why?
| | Physicians | 1 | 2013 | 934 | 0.050 |
Why?
| | Brain Infarction | 1 | 2023 | 23 | 0.050 |
Why?
| | DNA, Viral | 1 | 2025 | 366 | 0.050 |
Why?
| | Troponin T | 1 | 2023 | 66 | 0.050 |
Why?
| | Models, Theoretical | 2 | 2021 | 585 | 0.050 |
Why?
| | X-Rays | 1 | 2022 | 31 | 0.050 |
Why?
| | DNA Helicases | 1 | 2024 | 140 | 0.050 |
Why?
| | Data Curation | 1 | 2022 | 19 | 0.050 |
Why?
| | Smartphone | 1 | 2023 | 91 | 0.050 |
Why?
| | Adrenal Glands | 1 | 2022 | 80 | 0.050 |
Why?
| | Quinazolines | 2 | 2013 | 250 | 0.050 |
Why?
| | Logistic Models | 2 | 2021 | 2086 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 5636 | 0.050 |
Why?
| | Limb Salvage | 1 | 2022 | 65 | 0.050 |
Why?
| | Health Services | 1 | 2022 | 118 | 0.050 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2024 | 192 | 0.050 |
Why?
| | Vagina | 1 | 2024 | 194 | 0.050 |
Why?
| | Utilization Review | 1 | 2021 | 41 | 0.040 |
Why?
| | Receptors, GABA | 1 | 2021 | 14 | 0.040 |
Why?
| | Edema | 1 | 2022 | 131 | 0.040 |
Why?
| | Nepal | 1 | 2021 | 31 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 419 | 0.040 |
Why?
| | Genetic Therapy | 1 | 2023 | 315 | 0.040 |
Why?
| | Massachusetts | 1 | 2021 | 174 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3588 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2021 | 244 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 1052 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1859 | 0.040 |
Why?
| | Abdomen | 1 | 2021 | 136 | 0.040 |
Why?
| | Seizures | 1 | 2024 | 442 | 0.040 |
Why?
| | Incidence | 2 | 2020 | 2794 | 0.040 |
Why?
| | Internationality | 1 | 2021 | 158 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2024 | 624 | 0.040 |
Why?
| | Ankle | 1 | 2020 | 61 | 0.040 |
Why?
| | Models, Statistical | 2 | 2016 | 671 | 0.040 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 29 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 2023 | 411 | 0.040 |
Why?
| | Disease Progression | 2 | 2020 | 2793 | 0.040 |
Why?
| | Hand Bones | 1 | 2018 | 3 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 2020 | 146 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2024 | 712 | 0.040 |
Why?
| | Risk | 1 | 2021 | 904 | 0.040 |
Why?
| | Bevacizumab | 1 | 2019 | 139 | 0.040 |
Why?
| | Quality Control | 1 | 2019 | 171 | 0.040 |
Why?
| | Arthroscopy | 1 | 2021 | 238 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 814 | 0.040 |
Why?
| | Radiation Exposure | 1 | 2019 | 55 | 0.040 |
Why?
| | Reference Values | 1 | 2020 | 805 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 283 | 0.040 |
Why?
| | Hyperlipidemias | 1 | 2019 | 125 | 0.040 |
Why?
| | Medical Oncology | 1 | 2021 | 316 | 0.040 |
Why?
| | Hemizygote | 1 | 2017 | 5 | 0.040 |
Why?
| | Carbon Tetrachloride | 1 | 2017 | 13 | 0.030 |
Why?
| | Diabetic Retinopathy | 1 | 2020 | 200 | 0.030 |
Why?
| | Half-Life | 1 | 2017 | 146 | 0.030 |
Why?
| | Diffusion | 1 | 2017 | 121 | 0.030 |
Why?
| | Permeability | 1 | 2017 | 166 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 378 | 0.030 |
Why?
| | Skull | 1 | 2018 | 151 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2017 | 92 | 0.030 |
Why?
| | Outpatients | 1 | 2021 | 420 | 0.030 |
Why?
| | Ecosystem | 1 | 2022 | 583 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 704 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2017 | 330 | 0.030 |
Why?
| | Signal-To-Noise Ratio | 1 | 2016 | 67 | 0.030 |
Why?
| | Information Dissemination | 1 | 2019 | 224 | 0.030 |
Why?
| | Expert Systems | 1 | 2016 | 4 | 0.030 |
Why?
| | Prostate | 1 | 2017 | 173 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2021 | 683 | 0.030 |
Why?
| | Palate, Soft | 1 | 2016 | 15 | 0.030 |
Why?
| | Heart Ventricles | 1 | 2021 | 752 | 0.030 |
Why?
| | Video Recording | 1 | 2017 | 190 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2016 | 144 | 0.030 |
Why?
| | Transcription Factors | 1 | 2024 | 1703 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 2016 | 175 | 0.030 |
Why?
| | Antineoplastic Protocols | 1 | 2015 | 2 | 0.030 |
Why?
| | Magnetic Resonance Angiography | 1 | 2017 | 248 | 0.030 |
Why?
| | Molecular Imaging | 1 | 2016 | 55 | 0.030 |
Why?
| | Platelet Count | 1 | 2015 | 89 | 0.030 |
Why?
| | Perfusion | 1 | 2016 | 228 | 0.030 |
Why?
| | Radiotherapy Dosage | 1 | 2016 | 281 | 0.030 |
Why?
| | Motion | 1 | 2015 | 100 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 2017 | 271 | 0.030 |
Why?
| | Diffusion Tensor Imaging | 1 | 2015 | 78 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 715 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 868 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1556 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 2014 | 39 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2017 | 739 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1662 | 0.030 |
Why?
| | Image Enhancement | 1 | 2015 | 191 | 0.030 |
Why?
| | Carcinoma | 1 | 2016 | 230 | 0.030 |
Why?
| | DNA Modification Methylases | 1 | 2013 | 17 | 0.030 |
Why?
| | DNA Repair Enzymes | 1 | 2013 | 29 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2015 | 230 | 0.020 |
Why?
| | Argentina | 1 | 2013 | 28 | 0.020 |
Why?
| | Child, Preschool | 2 | 2018 | 11457 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1653 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 419 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2013 | 434 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 2013 | 175 | 0.020 |
Why?
| | Adolescent | 3 | 2018 | 22007 | 0.020 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2013 | 231 | 0.020 |
Why?
| | Life Tables | 1 | 2011 | 20 | 0.020 |
Why?
| | Smoking | 1 | 2019 | 1601 | 0.020 |
Why?
| | Effect Modifier, Epidemiologic | 1 | 2011 | 9 | 0.020 |
Why?
| | Hemodynamics | 1 | 2016 | 1100 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 855 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 325 | 0.020 |
Why?
| | Time Factors | 1 | 2022 | 6956 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2255 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 7070 | 0.020 |
Why?
| | Educational Status | 1 | 2013 | 463 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1056 | 0.020 |
Why?
| | Probability | 1 | 2011 | 309 | 0.020 |
Why?
| | Hypertension | 1 | 2019 | 1252 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 1074 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2011 | 326 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1820 | 0.020 |
Why?
| | Rats | 1 | 2017 | 5629 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 908 | 0.020 |
Why?
| | PubMed | 1 | 2008 | 11 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 755 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4404 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2011 | 1398 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1171 | 0.010 |
Why?
| | Internship and Residency | 1 | 2014 | 1235 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3292 | 0.010 |
Why?
| | Mice | 1 | 2017 | 18048 | 0.010 |
Why?
| | Animals | 1 | 2017 | 37657 | 0.010 |
Why?
|
|
Kalpathy-Cramer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|